Shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) saw strong trading volume on Wednesday . 730,510 shares traded hands during mid-day trading, a decline of 11% from the previous session’s volume of 818,345 shares.The stock last traded at $0.89 and had previously closed at $0.90.

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of DelMar Pharmaceuticals in a research report on Thursday. Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th. Finally, Maxim Group cut shares of DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.

The firm’s 50-day moving average is $1.14 and its 200 day moving average is $2.18. The firm’s market cap is $18.96 million.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Sabby Management LLC acquired a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned 4.79% of DelMar Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 13.74% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.